Title
Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia
Publication Date
2019
Journal Title
J Pharm Pract
Abstract
© The Author(s) 2019. Sacubitril/valsartan (Entresto®) is the first commercially available angiotensin receptor neprilysin inhibitor (ARNI) approved for use in heart failure patients with a reduced ejection fraction. It is a combination drug that contains sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker. Our report outlines a case of probable ARNI-induced hyponatremia occurring in an elderly woman with heart failure with a reduced ejection fraction. According to Naranjo Adverse Drug Reaction Assessment, score indicated a likely association between patient’s hyponatremia and her use of sacubitril/valsartan.
Document Type
Article
Status
Faculty
Facility
School of Medicine
Primary Department
Cardiology
PMID
DOI
10.1177/0897190019828915